CN114606232B - Cow mastitis related lncRNA and application thereof - Google Patents
Cow mastitis related lncRNA and application thereof Download PDFInfo
- Publication number
- CN114606232B CN114606232B CN202111300489.0A CN202111300489A CN114606232B CN 114606232 B CN114606232 B CN 114606232B CN 202111300489 A CN202111300489 A CN 202111300489A CN 114606232 B CN114606232 B CN 114606232B
- Authority
- CN
- China
- Prior art keywords
- lncrna
- mastitis
- dairy cow
- bmncr
- cow mastitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000004396 mastitis Diseases 0.000 title claims abstract description 54
- 108020005198 Long Noncoding RNA Proteins 0.000 title claims abstract 13
- 241000283690 Bos taurus Species 0.000 claims abstract description 74
- 235000013365 dairy product Nutrition 0.000 claims abstract description 57
- 210000001519 tissue Anatomy 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 19
- 210000002919 epithelial cell Anatomy 0.000 claims description 19
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 14
- 108020004459 Small interfering RNA Proteins 0.000 claims description 10
- 230000003321 amplification Effects 0.000 claims description 9
- 210000005075 mammary gland Anatomy 0.000 claims description 9
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 9
- 208000031462 Bovine Mastitis Diseases 0.000 claims description 7
- 238000000746 purification Methods 0.000 claims description 3
- 108091092328 cellular RNA Proteins 0.000 claims description 2
- 210000000981 epithelium Anatomy 0.000 claims description 2
- 230000014509 gene expression Effects 0.000 abstract description 24
- 230000002757 inflammatory effect Effects 0.000 abstract description 13
- 206010061218 Inflammation Diseases 0.000 abstract description 10
- 238000011161 development Methods 0.000 abstract description 10
- 230000004054 inflammatory process Effects 0.000 abstract description 10
- 238000009395 breeding Methods 0.000 abstract description 7
- 230000001488 breeding effect Effects 0.000 abstract description 7
- 230000008569 process Effects 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 5
- 230000007246 mechanism Effects 0.000 abstract description 5
- 230000008844 regulatory mechanism Effects 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 4
- 108020004418 ribosomal RNA Proteins 0.000 abstract description 3
- 230000008685 targeting Effects 0.000 abstract description 3
- 108091046869 Telomeric non-coding RNA Proteins 0.000 description 55
- 238000006243 chemical reaction Methods 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 11
- 108090001005 Interleukin-6 Proteins 0.000 description 8
- 108091058560 IL8 Proteins 0.000 description 7
- 108090001007 Interleukin-8 Proteins 0.000 description 7
- 210000000481 breast Anatomy 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 241000191967 Staphylococcus aureus Species 0.000 description 6
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 5
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 5
- 108010065805 Interleukin-12 Proteins 0.000 description 5
- 102000013462 Interleukin-12 Human genes 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000010839 reverse transcription Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 235000020247 cow milk Nutrition 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 101150044508 key gene Proteins 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000011880 melting curve analysis Methods 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000012121 regulation of immune response Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000013334 tissue model Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention belongs to the technical field of molecular biology, and provides lncRNA related to dairy cow mastitis and application thereof. The invention utilizes the technology of removing ribosomal RNA to analyze and compare the difference of gene expression profiles in normal mammary tissue and inflammatory mammary tissue of Holstein cows, and identifies and screens out the key differential expression lncRNA BMNCR related to the mastitis of the cows. The lncRNA BMNCR is induced to be expressed in inflammatory mammary tissues, eliminates inflammatory reaction to a certain extent and participates in an autologous protection mechanism in the occurrence and development processes of dairy cow mastitis. Therefore, the discovery of the lncRNA BMNCR is helpful for understanding the molecular regulation mechanism of the occurrence and development of the dairy cow mastitis, lays an experimental foundation for developing the dairy cow mastitis targeting drugs and developing the resistance breeding, and has important application prospect.
Description
Technical Field
The invention belongs to the technical field of molecular biology, and particularly relates to a novel lncRNA BMNCR extracted from dairy cow mammary tissue and application thereof, and more particularly relates to application of the novel lncRNA BMNCR in preventing and treating dairy cow mastitis and developing resistance breeding and developing targeted drugs.
Background
The mammary gland is a main place for synthesizing milk, and the dairy cow mastitis affects the health of dairy cows and restricts the development of dairy cow industry. For a long time, the dairy cow mastitis causes difficult-to-estimate economic loss for the global dairy cow breeding industry, and as a common disease, the pathogenesis of the dairy cow mastitis is thoroughly researched, but the treatment of the dairy cow mastitis at home and abroad still looks rich and insufficient, so that the problem of high mastitis morbidity and low cure rate puzzles the existing technology. Clinical mastitis cows can lead to the reduction of cow milk quality, the rapid reduction of cow milk yield, the reduction of cow milk nutritive value, the rapid increase of veterinary diagnosis and treatment cost, medical cost and labor capacity of the breeding industry, and recessive mastitis is valued due to high infection rate, and particularly has great influence on milk yield. Thus, the problem of cow mastitis is urgent.
The occurrence and development of mastitis are the result of sequential expression and closure of a series of related genes, the phenotype of which has a special regulatory mechanism and a complex genetic basis. Specific immune signaling pathway activation is a determinant of mastitis occurrence, but this process relies on a close match of coding and non-coding genes. At present, research on the pathogenesis of dairy cow mastitis is mainly focused on gene structure analysis, key gene expression profile research and functional analysis, and the molecular regulation mechanism of the occurrence of dairy cow mastitis, especially the effect of long non-coding RNA (lncRNA) in the occurrence process of the dairy cow mastitis is still unclear, and the complex network connection and action mode between the non-coding RNA and the functional genes are still unclear.
The function of lncRNA is more difficult to determine than that of miRNA and protein, but its range of action is broad, and it is an important function in inflammatory response as a regulatory non-coding RNA. Many studies have shown that different types of lncRNA can play important roles in inflammatory reactions through various mechanisms, but there are few studies on the specific mechanisms of regulation of immune responses and gene expression in the function of lncRNA in the development and progression of mastitis and in the self-protection of the body against inflammation.
Disclosure of Invention
The invention aims to provide a novel lncRNA BMNCR related to dairy cow mastitis, which can obviously up-regulate the expression in staphylococcus aureus-induced mastitis and can obviously up-regulate the expression of inflammation related factors IL2, IL6 and IL8 by reducing the expression of the lncRNA BMNCR, so that the lncRNA BMNCR is induced to be expressed in inflammatory mammary tissues, and eliminates inflammatory reaction to a certain extent and participates in an autologous protection mechanism in the occurrence and development processes of the dairy cow mastitis. The discovery of the lncRNA BMNCR is helpful for understanding the molecular regulation mechanism of the occurrence and the development of the dairy cow mastitis, lays an experimental foundation for developing the dairy cow mastitis targeting drugs and developing the resistance breeding, and has important application prospect.
The technical scheme provided by the invention is as follows:
a lncRNA associated with bovine mastitis, the lncRNA predicted sequence is SEQ ID No.1.
Furthermore, the full-length sequence of the lncRNA is SEQ ID NO.2 by the RACE cloning technology.
The invention also provides application of the lncRNA related to the dairy cow mastitis in preparation of medicaments for detecting, preventing or treating the dairy cow mastitis or in breeding of dairy cow mastitis with disease resistance.
The invention also provides a preparation method of the lncRNA related to the dairy cow mastitis, which takes Total RNA of normal breast tissues of the dairy cow as a template, and carries out 3'RACE and 5' RACE amplification of the lncRNA BMNCR.
Further, the 3' RACE amplification primer sequences were as follows:
P1-F1 GTCATGAAGTAGCCCCACAACAAC;
P1-F2 CTGTTAATGGGATCAGCTCTGAAG。
further, the 5' RACE amplification primer sequences were as follows:
the invention also provides a detection amplification primer of the lncRNA related to the dairy cow mastitis, and the primer sequence is as follows:
P3-F:TGATGTGGGTGTCTGAGTTTC;
P3-R:GCGAGTTTGCCTTTGGTTG。
the invention also provides siRNA of lncRNA related to dairy cow mastitis, which has the following sequence:
P4:GCCAUAAAGCUUGAUAGUATT UACUAUCAAGCUUUAUGGCTT。
the invention also provides the lncRNA related to the dairy cow mastitis, and the method comprises the steps of primary culturing, purifying and subculturing the dairy cow mammary gland epithelial tissue to obtain primary dairy cow mammary gland epithelial cells, transfecting siRNA into the primary dairy cow mammary gland epithelial cells, extracting cell RNA, and obtaining the knockdown lncRNA related to the dairy cow mastitis.
Further, the real-time fluorescent quantitative PCR primer pair sequences of the inflammation-related factors IL1A, IL, IL6, IL8 and IL12 are P5, P6, P7, P8 and P9 respectively:
P5-F:GCTCAAAATGAAGACGAACCC;
P5-R:CAACTTTGGATGGGCAACTG;
P6-F:GCACCTACTTCAAGCTCTACG;
P6-R:GGGCGCGTAAAAGTCAAATG;
P7-F:AGAACGAGTATGAGGGAAAT;
P7-R:TGGCTGGAGTGGTTATTAG;
P8-F:AAGAATTGAGAGTTATTGAGAGT;
P8-R:CAGACCTCGTTTCCATTG;
P9-F:CACCAAAGATAAAACCAGCACAG;
P9-R:GGCACAGGGTTGTCATAAAAG。
the invention provides lncRNA related to the occurrence of dairy cow mastitis, and a ribosome RNA removal technology is used for obtaining the lncRNA with a predicted sequence shown as SEQ ID NO.1.
The invention provides a true full-length sequence of lncRNA, and the sequence is shown as SEQ ID NO.2. Wherein the primer pair sequence of the 3'RACE cloning experiment is P1, and the primer pair sequence of the 5' RACE cloning experiment is P2.
Preferably, the sample detected by the reagent is normal breast tissue of the dairy cow.
More preferably, this lncRNA is designated BMNCR.
The invention detects the expression level of the lncRNA BMNCR, and the primer pair sequence of the real-time fluorescent quantitative PCR amplification is P3.
Preferably, the samples detected by the reagent are normal breast tissue and inflammatory breast tissue of the dairy cows.
The invention provides an interference siRNA of lncRNA BMNCR, which has a sequence of P4 and detects the self-protection function of the lncRNA BMNCR in the occurrence and development processes of dairy cow mastitis.
The invention detects the expression level of inflammation related factors IL1A, IL, IL6, IL8 and IL12, and the primer pair sequences of the real-time fluorescence quantitative PCR amplification are P5, P6, P7, P8 and P9 respectively.
Preferably, the sample to be tested by the reagent is primary mammary epithelial cells of a cow.
More preferably, the siRNA transfected with lncRNA BMNCR is delivered to primary mammary epithelial cells of the cow for 48 hours.
Advantageous effects
The research establishes a staphylococcus aureus-induced cow mastitis model, and utilizes a high-throughput sequencing technology (ribosome RNA removal technology) to identify and screen a key lncRNA which obviously up-regulates expression in staphylococcus aureus-induced mastitis, and a real-time fluorescent quantitative PCR experiment further verifies that the lncRNA obviously up-regulates expression in inflammatory mammary tissue. The invention utilizes the technology of removing ribosomal RNA to analyze and compare the difference of gene expression profiles in normal mammary tissue and inflammatory mammary tissue of Holstein cows, and identifies and screens out the key differential expression lncRNA BMNCR related to the mastitis of the cows. The RACE technique cloned the full-length sequence of lncRNA and for this purpose lncRNA was designated BMNCR (Bovine Mastitis Related lncRNA). Then, the research further synthesizes lncRNA BMNCR siRNA interference sequences, transfects primary mammary epithelial cells of dairy cows, detects the expression changes of inflammatory related factors IL1A, IL2, IL6, IL8 and IL12, and discovers that the interference lncRNA BMNCR can obviously up-regulate the expression changes of the inflammatory factors IL2, IL6 and IL 8. The lncRNABMNCR is expressed in an induction way in inflammatory mammary tissues, eliminates inflammatory reaction to a certain extent and participates in an autologous protection mechanism in the occurrence and development processes of dairy cow mastitis. Therefore, the implementation of the research is helpful for understanding the molecular regulation mechanism of the occurrence and development of the dairy cow mastitis, lays an experimental foundation for developing the dairy cow mastitis targeting drugs and developing the resistance breeding, and has important application prospect.
Drawings
FIG. 1 is a model of normal mammary tissue and staphylococcus aureus successfully induced bovine mastitis tissue in cows;
FIG. 2 is a graph showing the distribution of the differential expression lncRNA of bovine mastitis screened by the technique of removing ribosomal RNA;
FIG. 3 is a gel electrophoresis chart of lncRNA 3' RACE results;
FIG. 4 is a gel electrophoresis chart of lncRNA 5' RACE results;
FIG. 5 shows the expression levels of lncRNA BMNCR in normal and inflammatory mammary gland tissue of cows;
FIG. 6 shows the expression levels of inflammatory-related factors IL1A, IL, IL6, IL8, IL12 in primary mammary epithelial cells of cows after interference with lncRNA BMNCR.
Detailed Description
The invention will now be described in further detail with reference to the drawings and examples. The following examples are only for illustrating the present invention and are not intended to limit the scope of the present invention. Unless otherwise specified, all experimental techniques involved in the examples are conventional techniques for cell biology or molecular biology, and are carried out under conventional conditions.
The dairy cow mastitis tissue model successfully induced by normal dairy cow mammary tissue and staphylococcus aureus is successfully constructed and stored in the early stage of the laboratory.
EXAMPLE 1 extraction of Total RNA from samples
After the experimental dairy cows are slaughtered, the mammary tissue is rapidly collected, cut into small pieces, filled into 5mL freezing tubes, put into liquid nitrogen for freezing, and then transferred to a refrigerator at-80 ℃ for long-term storage for extracting total RNA, the lncRNA in the dairy cow mastitis tissue induced by staphylococcus aureus is identified, the mammary tissue gene expression profile is analyzed, and 3 repetitions are set for each sample.
And (3) RNA extraction:
1. thawing frozen tissue samples at 4 ℃;
2. cutting off a 50ug tissue sample to a 1.5mL EP tube, adding 1000mL Trizol, grinding and mixing uniformly, and standing for 5min;
3. adding 200ml chloroform (volume ratio of chloroform to Trizol is 1:5), mixing, standing at 4deg.C for 15min;
centrifuging at 12000rpm at 4.4 ℃ for 15min;
5. carefully draw the supernatant to a new EP tube;
6. adding a proper amount of isopropanol (the volume ratio of the isopropanol to the Trizo1 is 1:1), reversing and mixing uniformly, and standing for 10min;
centrifuging at 12000rpm at 7.4 ℃ for 10min;
8. removing the upper layer centrifugate, and adding 75% ethanol (RNase inactivation);
centrifuging at 8000rpm at 9.4 ℃ for 5min;
10. reserving sediment, discarding upper layer centrifugate, standing for 5-10 min at room temperature;
11. dissolving and precipitating a proper amount of DEPC water, taking a proper amount of RNA solution to measure concentration and observing the extraction condition of RNA;
12. tag name, concentration and date, -80 ℃ for storage.
EXAMPLE 2 lncRNA BMNCR full-length RACE clone
3'RACE and 5' RACE of the lncRNA BMNCR were amplified from normal mammary tissue Total RNA of cows as a template.
(one) 3' RACE
1. Primer design and Synthesis
2. Reverse transcription
cDNA was synthesized using 3' -Full RACE Core Set with PrimeScript Rtase (Code No. 6106).
The reaction system:
reaction conditions: 42 ℃,60min to 70 ℃ and 15min
PCR amplification
PCR amplification was performed using TaKaRa Tks Gflex DNA Polymerase (Code No. R060A).
Outer PCR reaction system:
reaction conditions:
inner PCR reaction system:
reaction conditions:
the PCR product was subjected to 1 agarose gel electrophoresis at 5ul, and the result is shown in FIG. 3
(II) 5' RACE
1. Primer design and Synthesis
2.First-Strand cDNA Synthesis
UsingThe cDNA was synthesized by reverse transcription of RACE 5'/3' kit (Cat. No. 634860).
The reaction system:
1ul SMARTer II A oligo (24 uM) is added
Reaction conditions: 72 ℃,3min to 42 ℃ and 2min
The following components were then added:
adding 90ul Tricine-EDTA buffer, mixing
Reaction conditions: 42 ℃,90min to 70 ℃ for 10min
PCR amplification
PCR amplification was performed using TaKaRa Tks Gflex DNA Polymerase (Code No. R060A).
Outer PCR reaction system:
reaction conditions:
inner PCR reaction system:
reaction conditions:
the PCR product was subjected to 1 agarose gel electrophoresis at 5ul, and the result is shown in FIG. 4
EXAMPLE 3 expression level of lncRNA BMNCR
1. The total RNA samples were taken out and stored in a refrigerator at-80℃and thawed at room temperature, and a reverse transcription system was prepared in a 0.2mL PCR tube as follows.
Reverse transcription System 20.0. Mu.L: total RNA,1.0 μg;4 XgDNA wind Mix, 4.0. Mu.L; nuclear-free H2O was added to 16.0. Mu.L.
Reaction conditions: 42 ℃ for 2min.
5X No RT Control Mix, 4.0. Mu.L was added
Reaction conditions: 15min at 50℃and 2min at 85 ℃.
Component and volume System in qRT-PCR System
Total reaction system 20.0 μl: 2X AceQ Universal SYBR qPCR Master Mix 10.0.0. Mu.L; each of the upstream and downstream primers was 0.4. Mu.L, cDNA was 2.0. Mu.L, and 7.2. Mu.L of enzyme-free water was added.
Reaction conditions: pre-deformation at 95 ℃ for 5min, cyclic reaction (10 s at 95 ℃, 30s at 60 ℃) x 40 cycles.
The primer pair P3 of the reaction lncRNA BMNCR has the sequence of (5 '-3'):
P3-F:TGATGTGGGTGTCTGAGTTTC
P3-R:GCGAGTTTGCCTTTGGTTG
3. SYBR Green is used as a fluorescent marker, PCR reaction is carried out on a Light Cycler fluorescent real-time quantitative PCR instrument, and a target band is determined through melting curve analysis and electrophoresis, 2 -ΔΔ(CT) The method is used for relative quantitative analysis.
4. Statistical method
Experiments were performed in 3 replicates, and the data obtained were expressed as mean ± standard error, statistically analyzed using SPSS 18.0 statistical software, and the differences between the two were t-tested, which was considered statistically significant when P < 0.05.
5. Results
lncRNA BMNCR very significantly upregulates expression in inflammatory breast tissue.
Example 4 Synthesis and transfection of 4 lncRNA BMNCR siRNA
1. According to the full-length sequence of lncRNA BMNCR, lncRNA BMNCR siRNA sequence was designed, nucleotide sequence P4 was (5 '-3'):
P4:GCCAUAAAGCUUGAUAGUATT UACUAUCAAGCUUUAUGGCTT
2. primary culture of cow mammary epithelial cells
2.1 test animal draws: selecting dairy cows with lactation period and no recessive mastitis, and aseptically acquiring mammary tissue of the dairy cows by adopting a surgical operation method. The method comprises the following steps: health examination is carried out one week before operation, clinical observation is free of abnormality, detection of mastitis is carried out by CMT (California Mastitis Test), and dairy cows without mastitis can be adopted every 2 days. Conventional anesthesia, an incision of about 5cm in length was made at the center of the line from the base of the breast to the nipple, and about 5g of mammary tissue was collected, placed in a complete culture medium of DMEM/F12 (30% fetal bovine serum, 300U/mL penicillin, 300U/mL streptomycin) prepared in advance, and brought back to the laboratory for further treatment.
2.2 primary culture of mammary epithelial cells: the breast tissue was repeatedly rinsed with PBS and the remaining milk and blood were rinsed clean until the rinse was clear. The acinus was carefully picked up with sterile forceps, collected in a beaker, and minced with scissors (1X 1 mm) 3 ) Proper amount of pancreatin was added, mammary tissue was coarsely digested at 37 ℃, then tissue pieces were precipitated, and the supernatant was removed. Repeatedly washing tissue blocks with PBS, adding collagenase, shaking and digesting at 37deg.C for 2 hr, filtering, and collecting cells and cell clusters. Inoculating into 6-hole culture plate according to density, and adding 5% CO 2 Culturing in a saturated humidity cell incubator, and changing liquid every other day.
2.3 purification of mammary epithelial cells: according to the difference of sensitivity degree of mammary epithelial cells and fibroblasts to digestive juice, the differential time digestion method is adopted to remove the fibroblasts and enrich the mammary epithelial cells.
2.4 subculturing of mammary epithelial cells: after purification, when the mammary epithelial cells reach 80% confluence, the culture solution is discarded, and Ca-free mammary epithelial cells are used 2+ 、Mg 2+ Is washed with PBS. Then adding pancreatin and EDTA mixed digestive liquid to digest the cells. The cells were continuously observed under an inverted microscope, and after most of the cells were retracted, rounded, and the cell gap was enlarged, digestion was stopped, the cells were repeatedly blown, collected and counted at 1×10 5 Inoculating the culture plate with one/mL solution, adding 5% CO 2 Culturing in a saturated humidity cell incubator, and changing liquid every other day.
3. Transfection experiment of primary mammary gland epithelial cells of dairy cows
3.1 cow primary mammary epithelial cells were cultured to a density of about 70% with 6-well plates.
3.2 20pmol siRNA was dissolved in 50. Mu.LSerum-free medium (pre-warmed at 37 ℃ before use).
3.3 1. Mu.L lipo2000 was dissolved in 50. Mu.LIn serum-free medium (preheated at 37 ℃ before use), the mixture was left at room temperature for 5min.
3.4 mixing the diluted siRNA of the 2 tubes with lipo2000, and standing at room temperature for 20min.
3.5 during transfection, the medium in the 6-well plate was changed to serum-free medium, and the above mixture was added dropwise.
3.6 after 4-6 hours of incubation, the complete medium containing serum was changed.
Example 5 expression level of inflammation-related factor
According to example 4, after lncRNA BMNCR siRNA-36 hours of transfection of primary mammary epithelial cells of cows, cellular RNA was extracted with Trizol, by the method referred to example 1. Further, reverse transcription of RNA into cDNA was performed for a fluorescent quantitative PCR experiment, and the specific method was described in example 3. Wherein, the primer pairs of the inflammation-related factors IL1A, IL, IL6, IL8 and IL12 are P5, P6, P7, P8 and P9 respectively, and the specific sequences are as follows (5 '-3').
P5-F:GCTCAAAATGAAGACGAACCC
P5-R:CAACTTTGGATGGGCAACTG
P6-F:GCACCTACTTCAAGCTCTACG
P6-R:GGGCGCGTAAAAGTCAAATG
P7-F:AGAACGAGTATGAGGGAAAT
P7-R:TGGCTGGAGTGGTTATTAG
P8-F:AAGAATTGAGAGTTATTGAGAGT
P8-R:CAGACCTCGTTTCCATTG
P9-F:CACCAAAGATAAAACCAGCACAG
P9-R:GGCACAGGGTTGTCATAAAAG
The results show that:
after decreasing the expression of lncRNA BMNCR relative to control NC (Negative Control), the expression levels of inflammatory factors IL2, IL6, IL8 were significantly or very significantly up-regulated.
Sequence listing
<110> university of Yangzhou
<120> a dairy cow mastitis related lncRNA and application thereof
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 4206
<212> DNA/RNA
<213> Artificial sequence (Artificial Sequence)
<400> 1
gaacgtaaag aattaaggag tatcattaaa tgggcttatg atgaataata cattatctca 60
agaataatgc tttaattgct ggagacgcca taaagcttga tagtaataat tttattttaa 120
aatgacaaag atttctacat catgttaatt tagcctttga tacagtaata gaaacggctt 180
ttaaaaagat tcaaatacag aaaagcatta aggcgagagg tctggttaag cagatgggag 240
gtgatagaac tgcaaatatt agaattgtgg taacatttgt atatactaaa gataagaata 300
ctgtttctgt attaaagttg ataggaaaaa ctagttttac atttcttttt ccctcctgcc 360
aaatgagaat atgggatttg gtggccgaaa ttccagttag gtttgaaatt cttattaagg 420
acttggttat tagagctttt gcatcttctt tgatccaaag ttatttgctt ttcagctgaa 480
actgtttgct actaggttga acaaataaat aagcagcatc ttgaattcat tttagaactt 540
ggaatccagc atttaaagga caccaagagg ggcctattca ttggggtttt atttagctgg 600
gcagcaactt ctctttctgc ctggtgaaaa atggatgttt tctcctcgct caaacaacat 660
aatcctttct aatacaaaag atttagacct tggagtgtga agggttaatg gtggtccttc 720
cccgctgtcc tcccaccccc cagcttcacc cctgactgtt ttgacaacac ttttcaaagt 780
gtgacattcc aagcccctac ataacaatgt aatattactg taattacaca ggtcattaca 840
ttttaaatag agaacaataa aatgcttatc gccctgaaaa agaacaggtg ttcttgccct 900
tctttggtat ttatgctaat tgtttttcat ctccttgaga aatatttatg gcaaacatgt 960
ttagatttca atctcaaggc agcagtatta attccgtgct aatctttcta ggttggggtt 1020
taatgtctgc agtttggatt atgggctcaa cattcaccca ataagtcata ttttaatgat 1080
tataaattta atatgccagc gcttccacag tttgttgaaa tgaaagcctt gtgaaaaccc 1140
cagaaacaaa actatgaggc attcgggagc ctagagtgtt tatctggaag aagtgttttt 1200
ggaaacttga ctgctgaagg aaagtagctt tcattgatgc acccctatct gattgagaaa 1260
agatttggag aaaaacaatc ccccattctg gctgggagtt ttccaccttg attttaattt 1320
tactgatacg gatttcattt agagtccctg ctggaaactg gtcagctttc tgtttcttag 1380
caagctgtga aaaagttaca ggaaggtttc cgggggctgg cagatcaaga atgctgttct 1440
gttagcagtt caggataact gcagttctgc acgccattaa aaaaatattt gctttagaaa 1500
accagcattt taatagttgc accagaggct gtgcttttaa agattacagt agaagtcttt 1560
ccaggttttg aatgtttcct cacatgccac gaggtgcctg tgtgcatacg aaaagcaccc 1620
agacttcttg gtggagaaat gttggtgcaa cttctcttac acaggctcag tgggtaaact 1680
ggaaggtatg taagaggatt ttacattttg tcagatgttt cacaacaggg gcccccgaat 1740
cacattaaaa atgcactgca gagacaggac agctgcaaat ttttgtgcgg acgcgtgttt 1800
ctggaccatg actaaaactc cggggacctt ttccccagct gtctggaagt tctgtggaag 1860
ttggtttatt ggcagttaag tctgagacaa cctggattta gcaaagactc tcctacacag 1920
gaagtagatg acattatatt gggggaaggg acttcaggca aggagtgatt tactcctttt 1980
ttgttttttt ttttaaaccg tggcgttgcc aaataaataa gcactttcca aggaagtagg 2040
tgtaagcttt ttagtcttgg tgagtggaaa tagataatat ctttaaccgc atttataact 2100
gtttcgaggt gacacatttc agaagtttgg agaaggaggg gggtgaatca aattcttgag 2160
gcttttcttt ttgaaagggg tgtgtgatgt gggtgtctga gtttcttctg ggagtggata 2220
ttggcaaccg tgtaagtcaa tcttcaactc tgacttataa ttgagcacat ttgtgaagga 2280
aatggttaat tttacaacca aaggcaaact cgcacctcga caggtctgct gaaagaaatg 2340
tgccctagtc ctttgctggc aagcaccacc gggtcataaa tccacaggct ttatttacag 2400
cccataacac ttatgaatgt taagatattt gacgccacgt tggccttata atattcaagg 2460
tctgcagaca ctggcagtag ctcaaatttc tctcactaat tataagcaat gagatggggg 2520
ggggtggaga cagcccatcg ccaaagctgc cctctccccc gcctctgacc cccaccctta 2580
caatctgagc caaccgagac agacaccccc tcctcctctg gcagctgact tgtacttttc 2640
ctccaggcta ttgttataca catttataaa gagcactttc aggaatggaa attcagtggg 2700
ggctctgcac gaatgttttt caaaagcaaa gttgctttag gtgtttgcat cttttttcct 2760
tttcttctgg tttatccctt tttcctttct ttcttgactt tttttttttt ttttggagac 2820
cctgttttct atattgtgct tatttcccag aatacttaaa gaaacctaat atgggaggct 2880
gcccttcaat ttacatgatg tttcactgag ctggaaggga aaacgtacgc attgcatagt 2940
gcgctagcta acgtgagggt taaaagaaaa gtgacgtgga gtgaggagaa ttgattaaaa 3000
gaattaatag atgaggaaaa aaaagccaag tttgctttgg gaatgggaag gccattcatt 3060
tgggaaatgt gcagtggtgt cttggtggag gacatagaaa tgtaacagag aaggcagaat 3120
aaatgcttgg ctaagaaagg ttagaaaggc ataaaaagat gcggcagaga tttgggctgg 3180
acaaaaatgg cttcattgaa attaggagtt agaagtttct gatgagaggt gaaaatacca 3240
tgactggggg ctggggtggg ggatggtatt aacaaccata ttgatttgct cagtaaaaac 3300
tggttccaat ctagttttca cccaaagagc tctgtgcagc agataataat ttcatgtgag 3360
ttaccgtgca agagtctggg gaaggggcat ctgtggtgaa gacccccgat gtgagagaga 3420
tggccagtta ccctgtggat tgtaatttat tcttaaaaaa ggagtgggct gtcctggtgt 3480
ttgtgtgacc acatggcaaa gggggagtgg gattccgagg tgtgtgggaa actgtggcaa 3540
agaggggcgg ggctgatggc tgtgtcattt ctggccgggt ccttcgctcc atccaaccca 3600
aacttaaaga ctgaggctga acggttttat tttctaatca atggaatgca gaaacttact 3660
agccctctgg gacagatagg aatcccttaa cagctcatta caaagatggg gctgtgggat 3720
ctttgaacgg gttatcagcc ctggtgttct ttggttttcc taggataggc tgttttcttc 3780
cttaggcata tctgatttgg ggctggtaat ttggtctctt atattttatc cttttttttt 3840
tttggtcatg aagtagcccc acaacaactc cttctgcagg gaaaagggat ggctgttaat 3900
gggatcagct ctgaaggagt taaaatggct tgctaaagtt tggcatcatg aaaataaatt 3960
tgaggcctgg taggcattag taaggcacag cacatttaca gagcttaatt agtacgaact 4020
gtaattgttc atggtctgcc agaagaagta atgttcagga aaagtggagt ccttctcttg 4080
cagtctttag tttgaaaccg ataaatcact tgcatatttg tgtagtgatt caaatggagc 4140
taagacctct cccatcccaa catgtggtaa attgtaaagt caatgaattg cagatgtagg 4200
ctacag 4206
<210> 2
<211> 6058
<212> DNA/RNA
<213> Artificial sequence (Artificial Sequence)
<400> 2
gagtgtacct gtaagcagtt gcatcctttc aaaagcaagc tctttggatt cctggtttct 60
gcttttctat ttaagaacgt aaagaattaa ggagtatcat taaatgggct tatgatgaat 120
aatacattat ctcaagaata atgctttaat tgctggagac gccataaagc ttgatagtaa 180
taattttatt ttaaaatgac aaagatttct acatcatgtt aatttagcct ttgatacagt 240
aatagaaacg gcttttaaaa agattcaaat acagaaaagc attaaggcga gaggtctggt 300
taagcagatg ggaggtgata gaactgcaaa tattagaatt gtggtaacat ttgtatatac 360
taaagataag aatactgttt ctgtattaaa gttgatagga aaaactagtt ttacatttct 420
ttttccctcc tgccaaatga gaatatggga tttggtggcc gaaattccag ttaggtttga 480
aattcttatt aaggacttgg ttattagagc ttttgcatct tctttgatcc aaagttattt 540
gcttttcagc tgaaactgtt tgctactagg ttgaacaaat aaataagcag catcttgaat 600
tcattttaga acttggaatc cagcatttaa aggacaccaa gaggggccta ttcattgggg 660
ttttatttag ctgggcagca acttctcttt ctgcctggtg aaaaatggat gttttctcct 720
cgctcaaaca acataatcct ttctaataca aaagatttag accttggagt gtgaagggtt 780
aatggtggtc cttccccgct gtcctcccac cccccagctt cacccctgac tgttttgaca 840
acacttttca aagtgtgaca ttccaagccc ctacataaca atgtaatatt actgtaatta 900
cacaggtcat tacattttaa atagagaaca ataaaatgct tatcgccctg aaaaagaaca 960
ggtgttcttg cccttctttg gtatttatgc taattgtttt tcatctcctt gagaaatatt 1020
tatggcaaac atgtttagat ttcaatctca aggcagcagt attaattccg tgctaatctt 1080
tctaggttgg ggtttaatgt ctgcagtttg gattatgggc tcaacattca cccaataagt 1140
catattttaa tgattataaa tttaatatgc cagcgcttcc acagtttgtt gaaatgaaag 1200
ccttgtgaaa accccagaaa caaaactatg aggcattcgg gagcctagag tgtttatctg 1260
gaagaagtgt ttttggaaac ttgactgctg aaggaaagta gctttcattg atgcacccct 1320
atctgattga gaaaagattt ggagaaaaac aatcccccat tctggctggg agttttccac 1380
cttgatttta attttactga tacggatttc atttagagtc cctgctggaa actggtcagc 1440
tttctgtttc ttagcaagct gtgaaaaagt tacaggaagg tttccggggg ctggcagatc 1500
aagaatgctg ttctgttagc agttcaggat aactgcagtt ctgcacgcca ttaaaaaaat 1560
atttgcttta gaaaaccagc attttaatag ttgcaccaga ggctgtgctt ttaaagatta 1620
cagtagaagt ctttccaggt tttgaatgtt tcctcacatg ccacgaggtg cctgtgtgca 1680
tacgaaaagc acccagactt cttggtggag aaatgttggt gcaacttctc ttacacaggc 1740
tcagtgggta aactggaagg tatgtaagag gattttacat tttgtcagat gtttcacaac 1800
aggggccccc gaatcacatt aaaaatgcac tgcagagaca ggacagctgc aaatttttgt 1860
gcggacgcgt gtttctggac catgactaaa actccgggga ccttttcccc agctgtctgg 1920
aagttctgtg gaagttggtt tattggcagt taagtctgag acaacctgga tttagcaaag 1980
actctcctac acaggaagta gatgacatta tattggggga agggacttca ggcaaggagt 2040
gatttactcc ttttttgttt ttttttttaa accgtggcgt tgccaaataa ataagcactt 2100
tccaaggaag taggtgtaag ctttttagtc ttggtgagtg gaaatagata atatctttaa 2160
ccgcatttat aactgtttcg aggtgacaca tttcagaagt ttggagaagg aggggggtga 2220
atcaaattct tgaggctttt ctttttgaaa ggggtgtgtg atgtgggtgt ctgagtttct 2280
tctgggagtg gatattggca accgtgtaag tcaatcttca actctgactt ataattgagc 2340
acatttgtga aggaaatggt taattttaca accaaaggca aactcgcacc tcgacaggtc 2400
tgctgaaaga aatgtgccct agtcctttgc tggcaagcac caccgggtca taaatccaca 2460
ggctttattt acagcccata acacttatga atgttaagat atttgacgcc acgttggcct 2520
tataatattc aaggtctgca gacactggca gtagctcaaa tttctctcac taattataag 2580
caatgagatg ggggggggtg gagacagccc atcgccaaag ctgccctctc ccccgcctct 2640
gacccccacc cttacaatct gagccaaccg agacagacac cccctcctcc tctggcagct 2700
gacttgtact tttcctccag gctattgtta tacacattta taaagagcac tttcaggaat 2760
ggaaattcag tgggggctct gcacgaatgt ttttcaaaag caaagttgct ttaggtgttt 2820
gcatcttttt tccttttctt ctggtttatc cctttttcct ttctttcttg actttttttt 2880
ttttttttgg agaccctgtt ttctatattg tgcttatttc ccagaatact taaagaaacc 2940
taatatggga ggctgccctt caatttacat gatgtttcac tgagctggaa gggaaaacgt 3000
acgcattgca tagtgcgcta gctaacgtga gggttaaaag aaaagtgacg tggagtgagg 3060
agaattgatt aaaagaatta atagatgagg aaaaaaaagc caagtttgct ttgggaatgg 3120
gaaggccatt catttgggaa atgtgcagtg gtgtcttggt ggaggacata gaaatgtaac 3180
agagaaggca gaataaatgc ttggctaaga aaggttagaa aggcataaaa agatgcggca 3240
gagatttggg ctggacaaaa atggcttcat tgaaattagg agttagaagt ttctgatgag 3300
aggtgaaaat accatgactg ggggctgggg tgggggatgg tattaacaac catattgatt 3360
tgctcagtaa aaactggttc caatctagtt ttcacccaaa gagctctgtg cagcagataa 3420
taatttcatg tgagttaccg tgcaagagtc tggggaaggg gcatctgtgg tgaagacccc 3480
cgatgtgaga gagatggcca gttaccctgt ggattgtaat ttattcttaa aaaaggagtg 3540
ggctgtcctg gtgtttgtgt gaccacatgg caaaggggga gtgggattcc gaggtgtgtg 3600
ggaaactgtg gcaaagaggg gcggggctga tggctgtgtc atttctggcc gggtccttcg 3660
ctccatccaa cccaaactta aagactgagg ctgaacggtt ttattttcta atcaatggaa 3720
tgcagaaact tactagccct ctgggacaga taggaatccc ttaacagctc attacaaaga 3780
tggggctgtg ggatctttga acgggttatc agccctggtg ttctttggtt ttcctaggat 3840
aggctgtttt cttccttagg catatctgat ttggggctgg taatttggtc tcttatattt 3900
tatccttttt tttttttggt catgaagtag ccccacaaca actccttctg cagggaaaag 3960
ggatggctgt taatgggatc agctctgaag gagttaaaat ggcttgctaa agtttggcat 4020
catgaaaata aatttgaggc ctggtaggca ttagtaaggc acagcacatt tacagagctt 4080
aattagtacg aactgtaatt gttcatggtc tgccagaaga agtaatgttc aggaaaagtg 4140
gagtccttct cttgcagtct ttagtttgaa accgataaat cacttgcata tttgtgtagt 4200
gattcaaatg gagctaagac ctctcccatc ccaacatgtg gtaaattgta aagtcaatga 4260
attgcagatg taggctacag tgagattctc taagaaaatg cagaatgaat gggaaagagt 4320
gatgctataa atatttactg agaagataac taggttcttg cgtgctgggc caattatgat 4380
gtactaagta tattagcaaa atgcttaaaa aaattgagag gatttgtatg ggtctttggg 4440
tgggttggtt tatttgggaa agtgaagtaa aaggcactat gttattgccc tgtcagtttt 4500
attaagcctg aatcacaatg gcatacccag ggaaggacac atgaaaccca cattaatgca 4560
aattaattcg ttgtgagttg cagcactgtg actgctaagt ggagtaatga tggggcatta 4620
ttttaagagt gttagtgtag caacttttaa tgaaaaatgc tgtgttagga acatgtctca 4680
gcactttagc ccacgtgttt ttatatgctg gaaatgtgtt ttggacaaga gcaggaaact 4740
tgcttcactt tattcttctc tctcccaaac agtttaagaa ctgtaattat ggtttgatgt 4800
ttaaagaaaa tcatctaatt ttccctcaaa aaacaaatcc agaaatgccc atcaccataa 4860
ccaagttcaa ctgtaacttt ttgcagtgac tgcaccacaa aatggaaaaa aaaaaatgta 4920
gctcccccca cgcccgccat aaacctatag atataacttt ctcaaagtga ttttctcttt 4980
tttttttttt ttttccttag agaattttgg tctcaggcag tgttgcaagt caatacttct 5040
ttccctcaat gtgagtaggt ggatgtgtat gaaagctgta aaagttaatg atcgttctct 5100
gactcatagc tgatggtttc aggttgagga aaagaaaaga aaaaattaat gagggtaaat 5160
agacatttga tggaacatcg agacagtagg agagattgtt cctgtgtcta aaggcgtgtg 5220
ttttgttgtg gcacaatttc tggagaaagc caggaaggga aaaggggttg cctttgttaa 5280
gttgttgttt taggagggta cagatgttct gtgtctggat ctttgcagga atgcttaagc 5340
ctccatccct accagtctgt gctggttttg ccttccctgt aggagttaga agcccccttg 5400
gcacttttta aaggggtagg gagacagaca cccagaggcc tggtcagaag tttatttccc 5460
agtaaatgta agaggctccc aacatagggc ttgggggtgc tgtcactgtc ctgaaaaatg 5520
acttgtgacc taagaaaagg tcttagatat acttgggccc ctattttgtc ttttatgcta 5580
atgacatgta aattaaactt aaagtgcctc ttggtggtag ctacagtggt gaggaaggtg 5640
aaccaagaat tcccccaaac cagaaccttt taggaaatga atctggattt cttcttcttt 5700
tttttttaaa tagaaagcta ggtgattcat aaaaatggaa ataaagcaaa tgctccccct 5760
cttctcagtt tagtggagtg agtaggcata cgaaattaat cttcatccta caggaagttc 5820
acttaagtgt tggaaaaccc aatggaaggt ttcaagtttt ttgagttgcc tttgaggatg 5880
agatctctgt ggctgaaaaa gctgcattgc ttttcttcca tctctgggta tctctgatgt 5940
cttgtatcgg aaacattgca tttaggtgcc attgccttct ccggtgactt tgggttaggt 6000
gcaatgattg cttcagacac aaaaaaggct caaaaaatgc tgataaactg gacttact 6058
Claims (5)
1. The dairy cow mastitis related lncRNA is characterized in that the sequence of the dairy cow mastitis related lncRNA is shown as SEQ ID NO.2.
2. The method for preparing lncRNA related to bovine mastitis according to claim 1, wherein the 3'race and 5' race amplification of lncRNA BMNCR is performed using Total RNA of normal mammary tissue of dairy cows as a template.
3. The method for preparing the lncRNA related to bovine mastitis according to claim 2, wherein the 3' race amplification primer sequence is as follows:
P1-F1 GTCATGAAGTAGCCCCACAACAAC ;
P1-F2 CTGTTAATGGGATCAGCTCTGAAG。
4. the method for preparing the lncRNA related to bovine mastitis according to claim 2, wherein the 5' race amplification primer sequence is as follows:
P2-RT1 TTTCTCAATCAGATAGGGGTGCAT;
P2-RT2 CTTCCAGATAAACACTCTAGGCTC;
P2-R3 TTTCAAACCTAACTGGAATTTCGG;
P2-R4 AAATCCCATATTCTCATTTGGCAG。
5. the method for preparing the lncRNA related to the dairy cow mastitis according to claim 2, wherein the primary mammary gland epithelial cells of the dairy cows are obtained after primary culture, purification and subculture of the mammary gland epithelial tissues of the dairy cows, siRNA is transfected into the primary mammary gland epithelial cells of the dairy cows, cellular RNA is extracted, and the knockdown lncRNA related to the dairy cow mastitis is obtained.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111300489.0A CN114606232B (en) | 2021-11-04 | 2021-11-04 | Cow mastitis related lncRNA and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111300489.0A CN114606232B (en) | 2021-11-04 | 2021-11-04 | Cow mastitis related lncRNA and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114606232A CN114606232A (en) | 2022-06-10 |
CN114606232B true CN114606232B (en) | 2023-12-08 |
Family
ID=81857235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111300489.0A Active CN114606232B (en) | 2021-11-04 | 2021-11-04 | Cow mastitis related lncRNA and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114606232B (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110376366A (en) * | 2019-07-19 | 2019-10-25 | 吉林大学 | A kind of niacin is applied to the experimental method for the treatment of mastadenitis of cow by GPR109A receptor |
CN110607324A (en) * | 2019-10-25 | 2019-12-24 | 扬州大学 | Dairy cow lysozyme gene mammary gland specificity expression recombinant plasmid and construction method and application thereof |
-
2021
- 2021-11-04 CN CN202111300489.0A patent/CN114606232B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110376366A (en) * | 2019-07-19 | 2019-10-25 | 吉林大学 | A kind of niacin is applied to the experimental method for the treatment of mastadenitis of cow by GPR109A receptor |
CN110607324A (en) * | 2019-10-25 | 2019-12-24 | 扬州大学 | Dairy cow lysozyme gene mammary gland specificity expression recombinant plasmid and construction method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN114606232A (en) | 2022-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104651509B (en) | Osteosarcomatous medicine new target drone | |
CN111154763B (en) | Application of long-chain non-coding RNA lncMGPF in regulation and control of pig muscle development function | |
CN107557472B (en) | Glioma diagnosis marker circ9:135881633|135883078 and application | |
CN111118170B (en) | Application of chi-miR-450-5p as goat follicle maturation miRNA marker | |
CN112618564B (en) | Inhibitor of hsa _ circ _0001400 and application of inhibitor in preparation of antitumor drugs | |
CN111172290B (en) | MiRNA for diagnosis and treatment of hepatocellular carcinoma | |
CN114606232B (en) | Cow mastitis related lncRNA and application thereof | |
CN110317878B (en) | Long-chain non-coding RNA for diagnosis and treatment monitoring of bladder cancer and application thereof | |
CN109402269B (en) | Application of reagent for detecting miRNA-217-5p in preparation of duck intestinal stress detection reagent | |
CN106434667B (en) | Relevant ring-type circRNA-016901 gene of a kind of leukaemia and application thereof | |
CN106191058B (en) | A kind of relevant ring-type circRNA-011235 genes of leukaemia and application thereof | |
CN114292850B (en) | circRNA related to proliferation and differentiation of goat myoblasts and application thereof | |
CN113355434B (en) | Marker Lnc-482286 related to porcine skeletal muscle satellite cell proliferation and application thereof | |
CN110511933B (en) | Rat long-chain non-coding lncRNA-lncMSTRG10078 and application thereof in resisting cell injury | |
CN110951880B (en) | Application of reagent for detecting lncRNA marker of hypopharynx cancer in preparation of product for diagnosing hypopharynx cancer | |
CN109172593B (en) | Application of miR-516a as target for treating bladder cancer | |
CN112522396A (en) | Child embryonic malignant tumor diagnostic reagent taking piRNA NU13 as detection target | |
CN111454949A (en) | Application of long-chain non-coding RNA L INC00702 as marker for diagnosing and treating bladder cancer | |
CN112980956B (en) | Target for inhibiting lung cancer growth and diagnostic marker uc.336 and application thereof | |
CN112280859B (en) | Breast cancer marker and application thereof | |
CN112481261B (en) | shRNA interference sequence of human AP-2 alpha gene and preparation and application thereof | |
CN114807135A (en) | Biological identification method and application of bovine skeletal muscle development related circular RNA circMYH8 | |
CN113186289B (en) | Application of lncRNA in renal cancer urine screening and renal cancer treatment | |
CN107916252B (en) | Immortalized lymphocyte strain for verifying spinal muscular atrophy | |
CN113817846A (en) | circRNA related to porcine luminal ovarian follicular atresia, siRNA inhibitor thereof and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |